drugset / Trial / NCT01115686

Branched-chain Aminoacids in Sleep Apnea Syndromes (ARSAS)

NCT01115686

Phase 3 Withdrawn University Hospital, Limoges
RandomizedParallel-groupTriple-blindTreatment

Summary

The initial hypothesis is that branched-chain aminoacids (BCAA) administration could be beneficial to patients suffering from sleep apnea syndrome (SAS), the aim of the present work is to verify this hypothesis. The literature data demonstrate that a BCAA complementation improves the physical performances, protects lean mass and increases VO2 max during training. We demonstrated earlier that this complementation can cure at less partly the hypoxemia of chronic obstructive pulmonary patients by a stimulation of respiratory centres.

Timeline

Start
2010-06
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Branched-Chain Amino Acids Other / unclassified 375 mg Oral

Indications